Atkinson PJ, Swami M, Ridgway N, Roberts M, Kinghorn J, Warner TT, Staddon JM, Takle AK. Advancing novel therapies for neurodegeneration through an innovative model for industry-academia collaborations: A decade of the
Eisai-UCL experience.
Drug Discov Today 2023;
28:103732. [PMID:
37541423 DOI:
10.1016/j.drudis.2023.103732]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 07/21/2023] [Accepted: 07/28/2023] [Indexed: 08/06/2023]
Abstract
External innovation initiatives in the pharmaceutical industry have become an integral part of research and development. Collaborations have been built to enhance innovation, mitigate risk, and share cost, especially for neurodegenerative diseases, a therapeutic area that has suffered from high attrition rates. This article outlines the Eisai-University College London (UCL) Drug Discovery and Development Collaboration as a case study of how to implement a productive industry-academic partnership. In the first 10 years, seven projects have been established and the first project, a novel anti-tau antibody for Alzheimer's disease, has entered clinical trials, providing early validation of this collaboration model.
Collapse